UBS Group’s Acer Therapeutics Inc ACER Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-94
| Closed | -$77 | – | 10448 |
|
|
2023
Q3 | $77 | Buy |
94
+61
| +185% | +$50 | ﹤0.01% | 8937 |
|
|
2023
Q2 | $30 | Hold |
33
| – | – | ﹤0.01% | 8656 |
|
|
2023
Q1 | $25 | Sell |
33
-1,360
| -98% | -$2.68K | ﹤0.01% | 9404 |
|
|
2022
Q4 | $3.5K | Sell |
1,393
-9,233
| -87% | -$15.8K | ﹤0.01% | 9502 |
|
|
2022
Q3 | $15K | Buy |
10,626
+10,593
| +32,100% | +$15.3K | ﹤0.01% | 7859 |
|
|
2022
Q2 | $0 | Hold |
33
| – | – | ﹤0.01% | 11295 |
|
|
2022
Q1 | $0 | Buy |
33
+7
| +27% | +$17 | ﹤0.01% | 11206 |
|
|
2021
Q4 | $0 | Sell |
26
-5,150
| -99% | -$12K | ﹤0.01% | 10961 |
|
|
2021
Q3 | $13K | Buy |
5,176
+2,907
| +128% | +$7.38K | ﹤0.01% | 7706 |
|
|
2021
Q2 | $6K | Sell |
2,269
-467
| -17% | -$1.34K | ﹤0.01% | 8481 |
|
|
2021
Q1 | $9K | Buy |
2,736
+604
| +28% | +$2.05K | ﹤0.01% | 8033 |
|
|
2020
Q4 | $6K | Buy |
2,132
+2,106
| +8,100% | +$5.67K | ﹤0.01% | 7791 |
|
|
2020
Q3 | $0 | Buy |
26
+15
| +136% | +$48 | ﹤0.01% | 8555 |
|
|
2020
Q2 | $0 | Sell |
11
-10,342
| -100% | -$29.2K | ﹤0.01% | 8487 |
|
|
2020
Q1 | $21K | Buy |
10,353
+1,173
| +13% | +$4.3K | ﹤0.01% | 6474 |
|
|
2019
Q4 | $37K | Buy |
9,180
+5,350
| +140% | +$18.2K | ﹤0.01% | 6530 |
|
|
2019
Q3 | $12K | Buy |
3,830
+3,582
| +1,444% | +$10.5K | ﹤0.01% | 7069 |
|
|
2019
Q2 | $1K | Buy |
+248
| New | +$4.73K | ﹤0.01% | 7757 |
|
|
2018
Q4 | – | Sell |
-2,276
| Closed | -$70K | – | 8395 |
|
|
2018
Q3 | $70K | Buy |
2,276
+847
| +59% | +$22.7K | ﹤0.01% | 5887 |
|
|
2018
Q2 | $31K | Buy |
+1,429
| New | +$27.1K | ﹤0.01% | 6359 |
|
|
2018
Q1 | – | Sell |
-1,337
| Closed | -$19K | – | 8264 |
|
|
2017
Q4 | $19K | Buy |
+1,337
| New | +$21.8K | ﹤0.01% | 6603 |
|
|
2017
Q3 | – | Sell |
-787
| Closed | -$5K | – | 8089 |
|
|
2017
Q2 | $5K | Sell |
787
-116
| -13% | -$769 | ﹤0.01% | 7144 |
|
|
2017
Q1 | $7K | Sell |
903
-491
| -35% | -$4.83K | ﹤0.01% | 6841 |
|
|
2016
Q4 | $13K | Buy |
1,394
+935
| +204% | +$16.4K | ﹤0.01% | 6776 |
|
|
2016
Q3 | $15K | Buy |
+459
| New | +$19.3K | ﹤0.01% | 6535 |
|
|
2016
Q2 | – | Sell |
-500
| Closed | -$12K | – | 8041 |
|
|
2016
Q1 | $12K | Buy |
+500
| New | +$11K | ﹤0.01% | 6551 |
|
|
2015
Q4 | – | Sell |
-198
| Closed | -$6K | – | 8643 |
|
|
2015
Q3 | $6K | Hold |
198
| – | – | ﹤0.01% | 7624 |
|
|
2015
Q2 | $7K | Buy |
198
+102
| +106% | +$3.92K | ﹤0.01% | 7724 |
|
|
2015
Q1 | $4K | Buy |
96
+22
| +30% | +$1.35K | ﹤0.01% | 8252 |
|
|
2014
Q4 | $4K | Buy |
+74
| New | +$5.35K | ﹤0.01% | 9142 |
|
Other funds holding ACER
UBS Group's ACER Position: Q4 2023 in Review
UBS Group sold out of Acer Therapeutics Inc (ACER) in Q4 2023, closing a stake of 94 shares — an estimated $77 sold.
UBS Group first reported a position in ACER in Q4 2014 and held it in 30 quarters. The position peaked at $70K in Q3 2018. 2 funds tracked by Wall St. Rank hold ACER as of Q4 2023.
- UBS Group reported no remaining Acer Therapeutics Inc position as of Q4 2023 after selling out during the quarter.
- UBS Group sold 94 Acer Therapeutics Inc shares in Q4 2023, an estimated $77.
- UBS Group first reported a position in Acer Therapeutics Inc in Q4 2014 and held it in 30 quarters.
- UBS Group's Acer Therapeutics Inc position peaked at $70K in Q3 2018.
- 2 funds tracked by Wall St. Rank held Acer Therapeutics Inc as of Q4 2023.
Based on UBS Group's 13F filing for Q4 2023, filed 9 Feb 2024.